608
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE: CLINICAL TRANSLATIONAL THERAPEUTICS

Antiangiogenic Agents for the Treatment of Nonsmall Cell Lung Cancer: Characterizing the Molecular Basis for Serious Adverse Events

&
Pages 460-471 | Published online: 08 Jul 2011
 

Abstract

Novel agents to reduce angiogenesis by targeting vascular endothelial growth factor and other proangiogenic signaling pathways are being developed for advanced nonsmall cell lung cancer. Antibody-based therapies (e.g., aflibercept) and multitargeted tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, and BIBF 1120) are being evaluated in phase III clinical trials. Some antiangiogenic agents have demonstrated distinct profiles in producing a variety of nonhematologic toxicities, including bleeding/hemorrhage, venous and arterial thromboembolic events, gastrointestinal perforation, hypertension, and proteinuria. Elucidating the molecular basis of these toxicities may lead to clinical benefits by improving patient selection and allowing for the development of effective prevention and management strategies.

ACKNOWLEDGMENTS

This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Copyediting, editorial, and production assistance were provided by Alyssa Tippens, PhD, of MedErgy, which was contracted by BIPI for these services. The authors meet the ICMJE criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), were involved at all stages of manuscript development, and fully accept responsibility for all content and editorial decisions. The authors received no compensation related to the development of the manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.